22nd Century Group Inc Sells GVB Biopharma for $2.25 Million

Business by 2FIRSTS.ai

Nov.29.2023

22nd Century Group Inc Sells GVB Biopharma for $2.25 Million

US cigarette manufacturer, 22nd Century Group Inc, has sold its cannabis subsidiary, GVB Biopharma, for $2.25 million, exiting the industry after less than 18 months.

According to a report by Journalnow on November 29, American cigarette manufacturer 22nd Century Group Inc has announced the sale of its cannabis subsidiary, GVB Biopharma, for a sum of $2.25 million. This move signifies the company's formal exit from the cannabis industry, which proved to be a significant financial burden in less than a year and a half.

According to regulatory documents released on Monday, the purchaser of GVB is Specialty Acquisition Corp, a professional acquisition company based in Nevada.

References:

[1] 22nd Century plans to exit cannabis business at steep loss

Also Read:

[1] 22nd Century Group Plans to Publicly Issue Stock and Warrants

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Lawmakers Clash as Mexico Moves to Criminalize Sale and Promotion of Vapes

Mexico’s Chamber of Deputies Health Commission has approved a bill establishing a total ban on vapes and e-cigarettes, with penalties ranging from one to eight years in prison and fines between Mex$11,000 and Mex$226,000 (USD ≈$600–$12,300). The proposal sparked controversy among opposition lawmakers, who argued that the legislation criminalizes users rather than focusing on regulation and prevention.

Nov.26 by 2FIRSTS.ai

Hungary’s Continental Tobacco Launches New Slay Nicotine Pouch Brand in UK Targeting Female Consumers

Hungary’s Continental Tobacco Group has launched its Slay nicotine pouch brand in the UK, featuring compact, pastel-toned packaging and backed by a multi-million-pound investment and retail pilot programme to build its presence in the local market.

Dec.03 by 2FIRSTS.ai

2Firsts Research | ZYN Launches Limited-Edition Coffee Flavours and Can Engraving Service at Stockholm Arlanda Airport

2Firsts observed that ZYN has introduced limited-edition coffee flavours and an on-site can engraving service in the duty-free zone at Stockholm Arlanda Airport, alongside the rollout of its upgraded packaging and independent core-shelf displays, forming a complete product presentation and consumer experience system.

Nov.17 by 2FIRSTS.ai

CSUR, the Research Institute Supporting Juul’s PMTA Research, Outlines a New Pathway for Nicotine Pouches

CSUR—the Research Institute Supporting Juul and NJOY’s successful PMTAs—assessed FDA’s pilot for nicotine pouches. The program expedites premarket review by deferring behavioral data to post-market reporting. CSUR says this could speed authorizations, but manufacturers must still produce behavioral and real-world evidence after a Marketing Granted Order to maintain compliance with public-health standards.